Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) EBT Margin (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EBT Margin for 11 consecutive years, with 6549.66% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin rose 1042615.0% to 6549.66% in Q3 2025 year-over-year; TTM through Dec 2025 was 34206.5%, a 3411206.0% decrease, with the full-year FY2025 number at 34873.75%, down 3467222.0% from a year prior.
  • EBT Margin was 6549.66% for Q3 2025 at Cartesian Therapeutics, up from 6732.55% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 6549.66% in Q3 2025 to a low of 6732.55% in Q2 2025.
  • A 5-year average of 393.63% and a median of 39.66% in 2022 define the central range for EBT Margin.
  • Biggest YoY gain for EBT Margin was 1042615bps in 2025; the steepest drop was -677749bps in 2025.
  • Cartesian Therapeutics' EBT Margin stood at 41.34% in 2021, then dropped by -19bps to 33.37% in 2022, then crashed by -1383bps to 428.16% in 2023, then skyrocketed by 778bps to 2903.95% in 2024, then skyrocketed by 126bps to 6549.66% in 2025.
  • Per Business Quant, the three most recent readings for RNAC's EBT Margin are 6549.66% (Q3 2025), 6732.55% (Q2 2025), and 4968.5% (Q1 2025).